| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA Date example | BLA | — | Subscribe to access the data. | Unknown | Unknown | ||
PDUFA Date example | BLA | — | Subscribe to access the data. | Unknown | Unknown | ||
PDUFA Date example | BLA | — | Subscribe to access the data. | Unknown | Unknown |
Recent Updates
Recently added Catalysts
Scholar Rock Holding Corporation$56.71
-1.23 (-2.12%)
C 44Pipeline Score Richly Valued Biotech · Commercial
Market Cap
5.77 B
EPS
-3.59
P/E Ratio
-
Value Trade
50.68 M
SEC Financials
Q1 2026Dilution Risk
25%Revenue
-
R&D Expenses
51.81 M
Operating CF
-82.10 M
Total Assets
535.25 M
Total Liabilities
259.24 M
Equity
276.01 M
D/E Ratio
12,345
-4.73 %
Week
-1.31 %
1 Month
1.58 %
3 Month
26.59 %
6 Month
73.01 %
5 Year
237.75 %
All Time
Cash Data
Cash Position
479.94 M
Monthly Burn
27.37 M
Runway
15.3 mo
Burn Trend
StableSEC Filing
May 7, 2026
Overview
Volume
829.11 K
52 Week Range
27.07 - 51.63
% held by Insiders
19.61 %
% held by Institutions
98.9 %
Enterprise Value
5.49 B
Total Shares
101.97 M
Short %
23.31 %
Float Shares
78.82 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Scholar Rock Holding Corporation
364Total events
9Upcoming
72Tier-1 (high impact)
2018 – 2026Coverage
Upcoming catalysts 9
Event history 355
Q3 2026
●Manufacturing MilestoneApitegromabApprovedCMC / Inspection
Commercial supply from second fill-finish facility expected early Q3 2026
spinal muscular atrophysource ↗
Jun 22, 2026
◆Oral PresentationPresentation
Oral presentation at 2026 International Research Congress on FSHD
Facioscapulohumeral Muscular Dystrophy (FSHD)source ↗
Jun 10, 2026
Jun 2026
◆EU MAA SubmissionApitegromabApprovedEx-US Regulatory
EMA MAA decision expected mid-2026
spinal muscular atrophysource ↗
Jun 2026
●Trial InitiationApitegromabApprovedTrial
Phase 2 FORGE trial initiation expected in mid-2026
facioscapulohumeral muscular dystrophysource ↗
Jun 2026
◆Other Regulator MilestoneApitegromabApprovedEx-US Regulatory
EMA decision on apitegromab MAA anticipated
spinal muscular atrophy (SMA)source ↗
Jun 2026
◆CHMP Positive OpinionApitegromabApprovedEx-US Regulatory
CHMP opinion for apitegromab MAA anticipated near mid-2026
spinal muscular atrophysource ↗
May 12, 2026
◆Oral PresentationPresentation
Scholar Rock management to present at BofA Securities 2026 Health Care Conference
May 7, 2026
▲FDA Filing AcceptedApitegromabApprovedRegulatory Filing
FDA accepted apitegromab BLA
spinal muscular atrophysource ↗
May 7, 2026
◆FDA Feedback ReceivedApitegromabApprovedFDA Meeting
FDA completed reinspection of Catalent Indiana facility
spinal muscular atrophysource ↗
May 7, 2026
●Enrollment UpdateApitegromabApprovedTrial
Enrollment progressing in Phase 2 OPAL trial
spinal muscular atrophy (infants/toddlers)source ↗
Drug Pipeline Intelligence
C44
Pipeline Score $704M
Pipeline ValueRichly Valued
Valuation Signal4
Drugs Scored0.1x
rNPV / MCap Top 63%
Small Cap (rank 338 of 912)
Percentile RankScholar Rock Holding Corporation carries a moderate pipeline score (44/100), with $1.1B risk-adjusted pipeline value, led by Apitegromab in Overweight and Obesity (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apitegromab Small molecule | Spinal Muscular Atrophy | Phase 3 | NCT05626855 | 44% | $780M | ACTIVE NOT_RECRUITING | 478 | VERY_FAST | D (32) | May 2, 2029 | LOW_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
apitegromab Priority | obesity | Phase 2 | 2025-06-18 | 100 subjects with obesity | Scholar Rock Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss • Patients receiving apitegroma Read More | |
apitegromab Priority | obesity | Phase 2 | 2025-06-18 | 100 subjects with obesity | Scholar Rock Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss • Patients receiving apitegroma Read More | |
apitegromab Priority | obesity | Phase 2 | 2025-06-18 | 100 subjects with obesity | Scholar Rock Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss • Patients receiving apitegroma Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in SRRK
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
SRRK Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
SRRKScholar Rock to Showcase Neuromuscular Research Portfolio at 2026 Annual Cure SMA Research and Clinical Care Meeting and 2026 International Research Congress on FSHD
Scholar Rock is set to present its neuromuscular research portfolio at two significant events in 2026: the Annual Cure SMA Research and Clinical Care Meeting and the International Research Congress on FSHD. These platforms will allow the company to share its advancements and findings in neuromuscular diseases. The presentations aim to foster collaboration and innovation in the field.
Read more →SRRKScholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Scholar Rock has reported new employee inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4). This announcement highlights the company's commitment to attracting talent as it continues to grow. The specifics of the inducement grants were not detailed in the report.
Read more →SRRK▲ +7%on this news
Scholar Rock to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
Scholar Rock is scheduled to present at the Goldman Sachs 47th Annual Global Healthcare Conference. The event will provide a platform for the company to discuss its developments and strategic initiatives in the biopharma sector. Further details about the presentation have not been disclosed.
Read more →SRRKScholar Rock to Present at the 2026 Jefferies Global Healthcare Conference
Scholar Rock is set to present at the 2026 Jefferies Global Healthcare Conference. The event will provide a platform for the company to share insights and updates regarding its ongoing projects and future directions. Details about the presentation and topics to be discussed have not been disclosed in the article.
Read more →SRRKScholar Rock Reports First Quarter 2026 Financial Results and Recent Business Highlights
Scholar Rock reported its first quarter 2026 financial results, highlighting the FDA's acceptance of the apitegromab BLA, which is set for a PDUFA date of September 30, 2026. The company is preparing for a commercial launch while continuing to advance its clinical pipeline, including the ongoing Phase 2 OPAL trial. Despite a net loss of $105.5 million, Scholar Rock maintains a strong financial position with $479.9 million in cash.
Read more →SRRKScholar Rock to Present at the BofA Securities 2026 Health Care Conference
Scholar Rock will present at the BofA Securities 2026 Health Care Conference on May 12, 2026. The presentation will focus on the company's efforts to improve treatments for spinal muscular atrophy and other neuromuscular diseases. A live webcast of the event will be available on their website, with a replay accessible for 90 days.
Read more →SRRKScholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 17, 2026
Scholar Rock has granted inducement equity awards totaling 89,304 shares to nine new employees. This includes stock options and restricted stock units, aimed at attracting talent under Nasdaq regulations. The awards are part of the company's strategy to enhance its workforce while focusing on developing treatments for spinal muscular atrophy and other rare diseases.
Read more →SRRKScholar Rock to Report First Quarter 2026 Financial Results on May 7, 2026
Scholar Rock has announced it will report its first quarter 2026 financial results on May 7, 2026, before market opening. A conference call will follow at 8:00 a.m. ET, accessible via their website. The company is dedicated to developing treatments for spinal muscular atrophy and other rare diseases.
Read more →SRRK▲ +14.1%on this news
Scholar Rock Resubmits Biologics License Application (BLA) to FDA for Apitegromab for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)
Scholar Rock has resubmitted its Biologics License Application (BLA) to the FDA for Apitegromab, aimed at treating spinal muscular atrophy (SMA) in both children and adults. This resubmission indicates ongoing efforts to gain regulatory approval for this treatment. Further details about the application process or expected timelines were not provided.
Read more →SRRK▲ +7%on this news
CORRECTING and REPLACING Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Scholar Rock reported its financial results for Q4 and full year 2025, highlighting a net loss of $91 million for the quarter. The company is focused on advancing its SMA treatment, apitegromab, and is preparing for a resubmission of its BLA pending FDA reinspection. The CEO expressed optimism for 2026 as a transformative year for the company.
Read more →SRRKScholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Scholar Rock reported its financial results for Q4 and full year 2025, highlighting a net loss of $377.9 million. The company is focused on advancing its apitegromab program for spinal muscular atrophy, with plans to resubmit its BLA following FDA reinspection of a key facility. The company anticipates significant developments in 2026, including a U.S. launch and ongoing clinical trials.
Read more →SRRKScholar Rock to Present at Upcoming Investor Conferences
Scholar Rock, a biopharmaceutical company specializing in treatments for spinal muscular atrophy and other neuromuscular diseases, has announced its participation in upcoming investor conferences. The company aims to improve the lives of patients through its innovative myostatin biology platform. Webcasts of the events will be available on their website for investors and the public.
Read more →SRRKScholar Rock to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026
Scholar Rock has announced it will report its fourth quarter and full year 2025 financial results on March 3, 2026. The company will host a conference call and webcast at 8:00 a.m. ET to discuss these results. Scholar Rock is dedicated to developing treatments for spinal muscular atrophy and other neuromuscular diseases.
Read more →SRRKScholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - January 16, 2026
Scholar Rock has granted inducement equity awards totaling 35,200 shares to two new employees. This includes stock options and restricted stock units, aimed at incentivizing talent acquisition under Nasdaq Listing Rule 5635(c)(4). The awards are part of the company's strategy to enhance its workforce as it develops treatments for neuromuscular diseases.
Read more →SRRKas of today and should not be relied upon as representing its views as of any subsequent date. All information in this press release is as of the date of the release, and Scholar Rock undertakes no duty to update this in
Scholar Rock has provided an update on its ongoing regulatory submissions and developments related to its leads, particularly apitegromab and SRK-439. The company reported positive advancements such as the initiation of commercial activities in Europe, but also acknowledged the risks of FDA approval for new submissions and the unpredictability of clinical trial outcomes. Financially, Scholar Rock maintains a strong position with cash funding expected into 2027, which supports its plans for growing its pipeline and addressing regulatory feedback. The company is slated to present at the upcoming J.P. Morgan Healthcare Conference, highlighting its strategic focus on neuromuscular diseases.
Read more →SRRKScholar Rock to Present at the 44th Annual J.P. Morgan Healthcare Conference
Scholar Rock will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12. The company is dedicated to developing treatments for spinal muscular atrophy and other neuromuscular diseases. A live webcast of the presentation will be available on their website, with a replay accessible for 90 days.
Read more →SRRK▲ +24.4%on this news
ir@scholarrock.com 917 -439 -0374 Media Contact Molly MacLeod media@scholarrock.com 802 -579 -5995
Scholar Rock released its financial results for the third quarter of 2025, reporting a net loss of $102.2 million. The company maintains a strong cash position with approximately $369.6 million, which is expected to fund operations into 2027. Despite significant investments in infrastructure and increased operational expenses in preparation for the launch of apitegromab, there are uncertainties about regulatory approval timelines and the company's ability to manage ongoing costs.
Read more →SRRKFDA Issues Complete Response Letter (CRL) for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA) Solely Related to Observations Identified at Catalent Indiana LLC Fill-Finish Facility No other app
Scholar Rock (NASDAQ: SRRK) announced that the FDA has issued a Complete Response Letter (CRL) for the apitegromab BLA intended for treating patients with spinal muscular atrophy. The CRL was prompted by observations made during an inspection of the Catalent Indiana LLC facility, though no specific concerns about the drug's efficacy or safety were cited. Scholar Rock is working closely with Catalent to resolve these manufacturing issues and plans to resubmit the BLA once corrective actions are implemented. There is optimism for a potential swift resubmission and approval after remediation is completed.
Read more →SRRK▼ -6.4%on this news
Other current assets 24,113 13,887 Total current assets 319,126 451,165 Other assets 20,919 23,757 Total assets $ 340,045 $ 474,922 Liabilities and Stockholders' Equity Current liabilities $ 50,435 $ 46,936 Long-term lia
Scholar Rock Holding Corporation reported a significant increase in operating expenses and a net loss of $110 million for the second quarter of 2025. The company's total assets declined from $474.9 million to $340.0 million, raising concerns regarding its financial health. The increase in expenses was primarily attributed to rising research and development and administrative costs. Scholar Rock highlighted ongoing risks related to the approval of its products and the dependency on clinical trial results for its future prospects.
Read more →SRRK▲ +16.6%on this news
Scholar Rock Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss • Patients receiving apitegroma
Scholar Rock reported positive results from its Phase 2 EMBRAZE trial for apitegromab, showcasing statistically significant preservation of lean mass in patients undergoing tirzepatide-induced weight loss. The trial, which involved 100 subjects with obesity, evaluated the efficacy, safety, and pharmacokinetics of apitegromab administered alongside tirzepatide. As a myostatin inhibitor, apitegromab aims to enhance muscle function in patients with spinal muscular atrophy (SMA). The study's outcomes could have implications for future regulatory approvals and treatment options in the obesity market.
Read more →SRRKScholar Rock Reports First Quarter 2025 Financial Results and Highlights Business Progress • Apitegromab BLA accepted under priority review for patients with Spinal Muscular Atrophy (SMA) and FDA's PDUFA date set
Scholar Rock announced its financial results for the first quarter of 2025, revealing significant advancements in its business, particularly the acceptance of the Biologics License Application (BLA) for apitegromab for spinal muscular atrophy. The organization reported a net loss of $74.7 million, which is an increase compared to the previous year's quarter. Despite losses, Scholar Rock maintains a solid cash position of approximately $364.4 million, which is expected to fund operations through 2027. The company has also appointed new executives to bolster its leadership team as it prepares for further regulatory and commercial activities.
Read more →SRRKScholar Rock Appoints David L. Hallal as Chief Executive Officer; Also Announces Addition of Three Key Leaders to Scale for Next Phase of Growth David Hallal has served as Chairman of the Board of Directors since 2017; e
Scholar Rock has appointed David L. Hallal as the new Chief Executive Officer, succeeding Jay Backstrom, M.D., who will now serve in a strategic advisory role. The company also announced the addition of three key leaders: Akshay Vaishnaw as President, R. Keith Woods as Chief Operating Officer, and Vikas Sinha as Chief Financial Officer. This leadership transition coincides with Scholar Rock's preparations for the global launch of apitegromab, a treatment aimed at spinal muscular atrophy, which has already received priority review status from regulatory authorities.
Read more →SRRKScholar Rock Reports Full Year 2024 Financial Results and Highlights Business Progress - Submitted apitegromab U.S. Biologics License Application (BLA) for patients with spinal muscular atrophy in January 2025; U.S. laun
Scholar Rock reported its financial results for the year ended December 31, 2024, highlighting a significant net loss of $246.3 million. The company submitted a U.S. Biologics License Application for apitegromab, aiming to treat spinal muscular atrophy, and is focused on advancing their clinical pipeline. Despite maintaining a strong cash reserve of $437.3 million, they face risks related to the predictability of clinical trial outcomes and competition from other developers in the market.
Read more →SRRKScholar Rock Announces the Appointment of Industry Leader Lisa Wyman as Chief Technical and Quality Officer and Planned Leadership Transition - Lisa Wyman brings more than 20 years of leadership and functional experience
Scholar Rock announced the appointment of Lisa Wyman as the new Chief Technical and Quality Officer as part of a leadership transition. Wyman brings over 20 years of technical and quality operations experience, joining the executive team to support the company's preparations for its first expected drug approval and commercial launch in 2025. During this period, Ted Myles will remain with the company to assist through the transition phase as Scholar Rock moves toward a new organizational structure.
Read more →SRRKxA9; 2025 Scholar Rock, Inc. All rights reserved. Forward-Looking Statements Various statements in this presentation concerning the future expectations, plans and prospects of Scholar Rock Holding Corporation and Scholar
Scholar Rock, Inc. is advancing with its investigational drug apitegromab, which demonstrates consistent clinical benefits in patients with spinal muscular atrophy (SMA). The safety profile has been favorable over the course of the Phase 2 TOPAZ trial, and the company anticipates submitting a Biologics License Application (BLA) and Marketing Authorization Application (MAA) by the first quarter of 2025. Despite these advancements, concerns regarding muscle weakness and loss in patients receiving GLP-1 receptor agonist treatments highlight ongoing challenges in muscle-targeted therapies. Topline data for ongoing studies are expected in Q2 2025, reflecting the company's commitment to addressing these concerns.
Read more →SRRK▲ +5.2%on this newsshared move
xA9; 2024 Scholar Rock, Inc. All rights reserved. Forward-Looking Statements Various statements in this presentation concerning the future expectations, plans and prospects of Scholar Rock Holding Corporation and Scholar
Scholar Rock, Inc. is pursuing treatment options targeting iron-restricted anemias associated with chronic conditions like chronic kidney disease and inflammation. The company's RGMc/HJV inhibitors are seen as promising due to their potential to improve patient outcomes and address the limitations of current therapies. Additionally, this pathway supports the establishment of an anemia franchise with possibilities for future indication expansions. Despite the opportunities, SRK-181 remains investigational and has not yet received FDA approval.
Read more →SRRK▼ -5.3%on this news
Scholar Rock Reports Third Quarter 2024 Financial Results and Highlights Business Progress - Reported positive topline data from pivotal Phase 3 SAPPHIRE trial evaluating apitegromab in patients with Spinal Muscular Atro
Scholar Rock (NASDAQ: SRRK) reported positive topline results from the Phase 3 SAPPHIRE trial for apitegromab, which targets spinal muscular atrophy. The trial's success underlines the drug's potential to become a new standard of care. Additionally, the company is preparing to submit for regulatory approval in early 2025. However, despite the positive news, Scholar Rock reported an increased net loss in its latest financial quarter.
Read more →SRRK▲ +362%on this news
Scholar Rock Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Scholar Rock announced a proposed public offering of common stock and pre-funded warrants, aiming to raise $275 million. This capital is intended to support the commercialization of its drug apitegromab and advance clinical programs. The offering is subject to market conditions and includes options for underwriters to purchase additional shares. Potential investors are advised that the actual size and terms of the offering could vary.
Read more →SRRK▲ +362%on this news
Scholar Rock Reports Apitegromab Meets Primary Endpoint in Phase 3 SAPPHIRE Study in Patients with Spinal Muscular Atrophy (SMA) Apitegromab met primary endpoint with statistically significant and clinically meaningful i
Scholar Rock announced that its investigational therapy, apitegromab, has met the primary endpoint in the Phase 3 SAPPHIRE study for patients with spinal muscular atrophy (SMA). The study showed a statistically significant improvement in motor function, with 30.4% of patients on apitegromab demonstrating a notable increase in scores compared to 12.5% on placebo. The company plans to submit a Biologics License Application in the U.S. and a marketing authorization application in the EU in Q1 2025. Overall, the trial results indicate promising outcomes for enhancing motor function in SMA patients across various age groups.
Read more →SRRKScholar Rock Reports Second Quarter 2024 Financial Results and Highlights Business Progress - Remains on track to report topline data from pivotal Phase 3 SAPPHIRE trial in patients with Spinal Muscular Atrophy (SMA) in
Scholar Rock has reported its financial results for the second quarter of 2024, showcasing business progress in its innovative treatments for spinal muscular atrophy (SMA) and other diseases. The company remains on track to release topline data from its pivotal Phase 3 SAPPHIRE trial of apitegromab, an investigational treatment for SMA, by the end of this year. Additionally, the company is advancing its cardiometabolic program with the EMBRAZE study in obesity, showing faster-than-expected enrollment. However, they noted an increased net loss in comparison to the previous year, and none of their therapies have received regulatory approval yet.
Read more →SRRKScholar Rock's subsequent filings with the Securities and Exchange Commission. Any forward-looking statements represent Scholar Rock's views only as of today and should not be relied upon as representing its views as of
Scholar Rock has dosed the first participants in the Phase 2 EMBRAZE trial, aimed at evaluating apitegromab for preserving lean muscle mass during GLP-1 receptor agonist therapy. The company also reported new preclinical data for SRK-439, indicating its potential to enhance lean mass and manage body composition after GLP-1 treatment withdrawal. The results suggest promising implications for weight management and overall metabolic health. Further updates on the EMBRAZE trial and the development of SRK-439 are anticipated.
Read more →SRRKScholar Rock Presents New Data from SRK-181 Phase 1 DRAGON Trial at ASCO 2024 Annual Meeting Promising objective response rates (ORR) were observed in multiple tumor types in anti-PD-(L)1 resistant patients Analysis of b
Scholar Rock reported promising interim results from its Phase 1 DRAGON trial of SRK-181, showing encouraging objective response rates in patients with advanced solid tumors resistant to anti-PD-(L)1 therapy. The therapy demonstrated anti-tumor activity particularly in clear cell renal cell carcinoma and melanoma, and safety data indicated it was generally well tolerated. New biomarker findings suggest potential strategies for patient selection, which the company plans to discuss with the FDA. The results were shared at the ASCO 2024 Annual Meeting, highlighting SRK-181's role in overcoming treatment resistance in various cancer types.
Read more →SRRKScholar Rock Announces Initiation of Phase 2 EMBRAZE Trial of Apitegromab in Obesity and New Preclinical Data Supporting SRK-439 in Obesity Phase 2 EMBRAZE proof-of-concept trial designed to assess apitegromab s ability
Scholar Rock has announced the initiation of its Phase 2 EMBRAZE trial to assess apitegromab's efficacy and safety in individuals with obesity. The trial aims to evaluate the preservation of lean muscle mass while patients are on GLP-1 receptor agonists. Additionally, new preclinical data indicates that SRK-439 may outperform other treatments in maintaining lean mass in these patients. The trial is set to enroll 100 subjects and expects to provide primary data by mid-2025.
Read more →SRRKScholar Rock Reports First Quarter 2024 Financial Results and Highlights Business Progress - On track to report topline data from pivotal Phase 3 SAPPHIRE trial in patients with Spinal Muscular Atrophy in 4Q 2024 - Initi
Scholar Rock has reported its financial results for Q1 2024 and highlighted its ongoing initiatives. The company is approaching the topline data readout for its Phase 3 SAPPHIRE trial in spinal muscular atrophy (SMA), expected in the fourth quarter of 2024. Additionally, Scholar Rock is progressing its cardiometabolic program and is set to present new preclinical data for SRK-439. Despite a notable increase in their financial losses, the leadership remains optimistic about the upcoming milestones.
Read more →SRRK▲ +14.8%on this news
Scholar Rock Reports Full Year 2023 Financial Results and Highlights Business Progress - Pivotal Phase 3 SAPPHIRE trial in patients with Spinal Muscular Atrophy on track to report topline data in 4Q 2024 - Announced FDA
Scholar Rock reported its full-year financial results for 2023, highlighting significant advancements in its clinical pipeline. The pivotal Phase 3 SAPPHIRE trial for apitegromab in spinal muscular atrophy is on schedule to deliver topline results in Q4 2024. The company also received FDA clearance to start a Phase 2 trial for apitegromab in obesity treatment. With a robust cash position, Scholar Rock is well-equipped to continue its development goals amid ongoing challenges, including a reported net loss of $165.8 million for the year.
Read more →SRRKScholar Rock Announces the Addition of Katie Peng to Its Board of Directors and Promotes Mo Qatanani, Ph.D. to Chief Scientific Officer CAMBRIDGE, Mass.--(BUSINESS WIRE)
Scholar Rock has appointed Katie Peng to its Board of Directors and promoted Mo Qatanani, Ph.D., to Chief Scientific Officer. Peng brings over 30 years of commercial experience in neurology and rare diseases, crucial for the anticipated launch of apitegromab. Qatanani has been instrumental in leading research efforts since joining the company, focusing on therapies for neuromuscular and cardiometabolic disorders. These leadership changes signal the company's commitment to advancing innovative treatments amid evolving market demands.
Read more →SRRK▲ +5.8%on this news
Scholar Rock, Inc. All rights reserved. Advancing New Possibilities for Patients 42nd ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE JANUARY 9, 2024 Scholar Rock, Inc. All rights reserved. 2024. Forward-Looking Statements Vari
Scholar Rock, Inc. is preparing for its participation at the 42nd Annual J.P. Morgan Healthcare Conference scheduled for January 9, 2024. The presentation includes forward-looking statements about the company’s strategy, product candidate selections, and the timing of clinical trials for its investigational therapies such as apitegromab, SRK-439, and SRK-181. Emphasis is placed on both the innovative potential of its pipeline and the associated risks, including challenges in drug development and competition in the biopharma sector.
Read more →SRRKScholar Rock Reports Third Quarter 2023 Financial Results and Highlights Business Progress Completed enrollment for pivotal Phase 3 SAPPHIRE trial evaluating apitegromab; topline data expected in 4Q 2024 Expanding into c
Scholar Rock reported its financial results for Q3 2023, highlighting significant advancements in its pipeline. The company completed enrollment for the Phase 3 SAPPHIRE trial of apitegromab, with topline data expected in Q4 2024. Additionally, there was positive data presented for SRK-181 in metastatic ccRCC patients. The company successfully raised $98 million from a public offering, extending its cash runway into the second half of 2025, allowing for continued development of its therapies.
Read more →SRRKScholar Rock Announces Proposed Public Offering of Common Stock CAMBRIDGE, Mass.--(BUSINESS WIRE)
Scholar Rock Holding Corporation has announced a proposed public offering of $75 million in common stock, which the company intends to use to advance its clinical pipeline, particularly its drug apitegromab. The offering is structured to allow the underwriters a 30-day option to purchase an additional 15% of shares. While the offering aims to enhance the company's resources for drug development, it is subject to market conditions, introducing potential uncertainties regarding completion and pricing.
Read more →SRRKScholar Rock TO ADVANCE ANTIMYOSTATIN PROGRAM to develop novel therapies for CARDIOMETABOLIC DISORDERS Company plans to expand into cardiometabolic disorders, leveraging its experience in myostatin inhibition Preclinical
Scholar Rock (NASDAQ: SRRK) has announced plans to advance its myostatin inhibitor, SRK-439, targeting obesity and cardiometabolic disorders. The company aims to submit an IND application by 2025 and initiate a Phase 2 trial in 2024, exploring a combination with GLP-1 receptor agonists. Scholar Rock emphasizes its strengths in developing selective myostatin inhibitors, which could help patients maintain muscle mass during weight loss treatments. However, the company also notes inherent uncertainties in the clinical development process, particularly regarding the prediction of outcomes from future trials.
Read more →SRRKScholar Rock Reports Second Quarter 2023 Financial Results and Highlights Business Progress - Recently presented 36-month apitegromab extension data from Phase 2 TOPAZ trial demonstrate long-term substantial and sustaine
Scholar Rock has reported its second quarter 2023 financial results, highlighting the progress of its apitegromab program. Recent data from the 36-month Phase 2 TOPAZ trial indicated substantial improvements in motor function for patients with spinal muscular atrophy. The ongoing Phase 3 SAPPHIRE trial is expected to complete enrollment in Q3 2023, with top-line data anticipated in the second half of 2024. Scholar Rock's financial position remains strong with an estimated $249 million in cash to support future operations.
Read more →SRRK▼ -10.5%on this news
New 36-Month Apitegromab Extension Data Reinforce Long-Term Substantial and Sustained Improvement of Motor Function in Phase 2 TOPAZ Trial Patients with Nonambulatory Spinal Muscular Atrophy - Improvements in patient-rep
Scholar Rock has released positive 36-month extension data from its Phase 2 TOPAZ trial, showing significant and sustained improvements in motor function for nonambulatory patients with spinal muscular atrophy (SMA). The study demonstrated enhancements in both motor function scores and patient-reported outcomes without new safety concerns. Additionally, the company is progressing towards its Phase 3 SAPPHIRE trial, expected to complete in Q3 2023, as interest in apitegromab as a potential treatment continues to grow. A virtual investor event is scheduled to discuss the future treatment landscape for SMA.
Read more →SRRK▲ +6%on this news
Scholar Rock Reports First Quarter 2023 Financial Results and Highlights Business Progress - Enrollment of pivotal Phase 3 SAPPHIRE trial evaluating apitegromab on track for completion in 2023 - Upcoming presentations of
Scholar Rock reported its first quarter 2023 financial results, highlighting significant advancements in their clinical trials, including the on-track enrollment of the Phase 3 SAPPHIRE trial for apitegromab. They expect to present 36-month data from the Phase 2 TOPAZ trial at the Cure SMA conference. The company maintains a strong cash position of approximately $275 million, allowing operations to continue into 2025, despite reporting an increase in net loss. Their ongoing commitment to develop innovative therapies for serious diseases was reaffirmed by the leadership.
Read more →SRRKScholar Rock Announces the Addition of Richard Brudnick to Its Board of Directors CAMBRIDGE, Mass.--(BUSINESS WIRE)
Scholar Rock has appointed Richard Brudnick as an independent director on its Board of Directors. Brudnick, who brings over 30 years of biotechnology experience, is expected to enhance the company's corporate development efforts as it advances its portfolio of innovative therapies. His previous roles include Chief Business Officer at Prime Medicine and leadership positions at Codiak BioSciences and Bioverativ. This appointment comes at a crucial time as Scholar Rock aims to develop treatments targeting serious diseases, including neuromuscular disorders and cancer.
Read more →SRRK▲ +6.6%on this news
Scholar Rock Reports Full Year 2022 Financial Results and Highlights Business Progress - Enrollment of pivotal Phase 3 SAPPHIRE trial evaluating apitegromab on track for completion in 2023, and 36-month extension data fr
Scholar Rock recently reported its full year 2022 financial results, highlighting significant progress in various clinical trials and corporate developments. The pivotal Phase 3 SAPPHIRE trial of apitegromab is set for enrollment completion in 2023, with promising 36-month extension data from the previous Phase 2 TOPAZ trial expected soon. The company ended 2022 with approximately $315 million in cash, providing sufficient funding to support operations into 2025. Additionally, Scholar Rock welcomed a new Chief Commercial Officer to assist with upcoming product launch strategies.
Read more →SRRKDeep InsightsAdvancingImpactful Medicines January 2023 Disclaimers Various statements in this presentation concerning the future expectations, plans and prospects of Scholar Rock, Inc. ("Scholar Rock"), including without
Scholar Rock, Inc. is focused on developing innovative therapies targeting high unmet medical needs, particularly through its drug candidates apitegromab and SRK-181. The company has a strong leadership team with a successful track record in clinical and commercial stages. Currently, Scholar Rock is conducting the Phase 3 SAPPHIRE study for apitegromab with results expected in 2024, alongside other studies in its robust pipeline. Despite current progress, all investigational drugs remain unapproved by the FDA and other regulatory agencies.
Read more →SRRKScholar Rock Reports Third Quarter 2022 Financial Results and Highlights Business Progress - Presented 24-month apitegromab data on quality-of life-measures from the TOPAZ trial and SRK-181 data from DRAGON trial at majo
Scholar Rock Reports Third Quarter 2022 Financial Results and Highlights Business Progress - Presented 24-month apitegromab data on quality-of life-measures from the TOPAZ trial and SRK-181 data from DRAGON trial at major medical/scientific congresses - Announced key leadership
Read more →SRRK▼ -5.9%on this newsshared move
Scholar Rock Appoints Jing L. Marantz, M.D., Ph.D., M.B.A., as Chief Medical Officer - Dr. Marantz brings over two decades of industry expertise across neurology, hematology/oncology, and rare diseases CAMBRIDGE, Mass.--
Scholar Rock Appoints Jing L. Marantz, M.D., Ph.D., M.B.A., as Chief Medical Officer - Dr. Marantz brings over two decades of industry expertise across neurology, hematology/oncology, and rare diseases CAMBRIDGE, Mass.--(BUSINESS WIRE)--November 9, 2022--Scholar Rock (NASDAQ: S
Read more →SRRKScholar Rock Appoints Jay Backstrom, M.D., M.P.H., to be its Next Chief Executive Officer - Dr. Backstrom brings more than 30 years of biopharmaceutical leadership experience, including most recently as Executive Vice Pr
Scholar Rock Appoints Jay Backstrom, M.D., M.P.H., to be its Next Chief Executive Officer CAMBRIDGE, Mass., September 20, 2022 (BUSINESS WIRE) -- Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in w
Read more →SRRKScholar Rock Reports Second Quarter 2022 Financial Results and Highlights Business Progress - Positive 24-month data from ongoing Phase 2 TOPAZ trial extension supports potential benefit of apitegromab for patients with
Scholar Rock Reports Second Quarter 2022 Financial Results and Highlights Business Progress - Positive 24-month data from ongoing Phase 2 TOPAZ trial extension supports potential benefit of apitegromab for patients with Types 2 and 3 Spinal Muscular Atrophy (SMA) - Actively enr
Read more →SRRKScholar Rock Announces the Addition of Srinivas Akkaraju, M.D., Ph.D. to Its Board of Directors
Scholar Rock Announces the Addition of Srinivas Akkaraju, M.D., Ph.D. to Its Board of Directors CAMBRIDGE, Mass.-July 26, 2022- Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth
Read more →SRRK▲ +10.9%on this news· ran to +28% by day 3
Positive Phase 2 Topaz Trial Extension Data Demonstrate Sizable and Sustained Motor Function Improvement at 24 Months with Apitegromab for Non-Ambulatory Patients with Types 2 and 3 Spinal Muscular Atrophy (SMA) - Sizabl
Positive Phase 2 Topaz Trial Extension Data Demonstrate Sizable and Sustained Motor Function Improvement at 24 Months with Apitegromab for Non-Ambulatory Patients with Types 2 and Muscular Atrophy (SMA) CAMBRIDGE, Mass., June 17, 2022 (BUSINESS WIRE) -- Scholar Rock (NASDAQ:
Read more →SRRK▲ +10.9%on this news· ran to +28% by day 3
Scholar Rock Announces $205 Million Registered Direct Offering CAMBRIDGE, Mass. (BUSINESS WIRE)
Rock Announces $205 Million Registered Direct Offering CAMBRIDGE, Mass. (BUSINESS WIRE) June 17, 2022 -- Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundame
Read more →SRRK▼ -6.6%on this news
Scholar Rock Reports First Quarter 2022 Financial Results and Updates Strategic Priorities - On track for Phase 2 apitegromab TOPAZ two-year data by mid-year - Progressed enrollment for both Phase 3 apitegromab SAPPHIRE
Scholar Rock Reports First Quarter 2022 Financial Results and Updates Strategic Priorities - On track for Phase 2 apitegromab TOPAZ two-year data by mid-year - Progressed enrollment for both Phase 3 apitegromab SAPPHIRE clinical trial & Phase 1 SRK-181 DRAGON clinical trial -
Read more →SRRKScholar Rock Reports Full Year 2021 Financial Results and Highlights Business Progress - Progressing Phase 3 SAPPHIRE clinical trial evaluating apitegromab in patients with non-ambulatory Type 2 and 3 Spinal Muscular Atr
Scholar Rock Reports Full Year 2021 Financial Results and Highlights Business Progress - Progressing Phase 3 SAPPHIRE clinical trial evaluating apitegromab in patients with non-ambulatory Type 2 and 3 Spinal Muscular Atrophy (SMA) - Two-year data from open label extension of TO
Read more →SRRKScholar Rock Provides Corporate Update and Highlights Priorities for 2022 - Initiated Phase 3 SAPPHIRE Clinical Trial Evaluating Apitegromab in Non-Ambulatory Patients with Type 2 and Type 3 Spinal Muscular Atrophy (SMA)
Scholar Rock Provides Corporate Update and Highlights Priorities for 2022 - Initiated Phase 3 SAPPHIRE Clinical Trial Evaluating Apitegromab in Non-Ambulatory Patients with Type 2 and Type 3 Spinal Muscular Atrophy (SMA) - Advanced DRAGON Phase 1 Study into Part B to Evaluate P
Read more →SRRKScholar Rock Announces Design of Phase 3 SAPPHIRE Clinical Trial Evaluating Apitegromab in Non-Ambulatory Patients with Type 2 and Type 3 Spinal Muscular Atrophy (SMA) - Phase 3 trial is a randomized, double-blind, place
Scholar Rock Announces Design of Phase 3 SAPPHIRE Clinical Trial Evaluating Apitegromab in Non-Ambulatory Patients with Type 2 and Type 3 Spinal Muscular Atrophy (SMA) - Phase 3 trial is a randomized, double-blind, placebo-controlled trial of apitegromab as add-on to background
Read more →SRRKScholar Rock Reports Third Quarter 2021 Financial Results and Highlights Business Progress - Phase 3 pivotal trial evaluating apitegromab in patients with non-ambulatory Type 2 and Type 3 SMA on track to initiate by year
Scholar Rock Reports Third Quarter 2021 Financial Results and Highlights Business Progress - Phase 3 pivotal trial evaluating apitegromab in patients with non-ambulatory Type 2 and Type 3 SMA on track to initiate by year-end 2021 - Update from Part A of the DRAGON Phase 1 trial
Read more →SRRKScholar Rock Reports Second Quarter 2021 Financial Results and Highlights Business Progress - Phase 3 trial to evaluate apitegromab in patients with non-ambulatory Type 2 and Type 3 spinal muscular atrophy (SMA) anticipa
Scholar Rock Reports Second Quarter 2021 Financial Results and Highlights Business Progress - Phase 3 trial to evaluate apitegromab in patients with non-ambulatory Type 2 and Type 3 spinal muscular atrophy (SMA) anticipated to initiate by end of 2021 - DRAGON Phase 1 trial eval
Read more →SRRK▼ -11.9%on this news
Scholar Rock Announces Leadership Change Nagesh Mahanthappa, Ph.D., MBA, Scholar Rock's founding chief executive, returns as Interim Chief Executive Officer as CEO Tony Kingsley departs CAMBRIDGE, Mass.--(BUSINESS WIRE)
Scholar Rock Announces Leadership Change Nagesh Mahanthappa, Ph.D., MBA, Scholar Rock's founding chief executive, returns as Interim Chief Executive Officer as CEO Tony Kingsley departs CAMBRIDGE, Mass.--(BUSINESS WIRE)--August 3, 2021--Scholar Rock (NASDAQ: SRRK), a clinical-s
Read more →SRRKApitegromab Positioned to be the Potential Next Transformative Therapy for Patients Suffering with SMA KOL Event and Panel Discussion
Apitegromab Positioned to be the Potential Next Transformative Therapy for Patients Suffering with SMA KOL Event and Panel DiscussionJune 15, 2021 Disclaimers Various statements in this presentation concerning the future expectations, plans and prospects of Scholar Rock, Inc.
Read more →SRRKDeep Insights,Impactful Medicines May 2021 Disclaimers Various statements in this presentation concerning the future expectations, plans and prospects of Scholar Rock, Inc. ("Scholar Rock"), including without limitation,
Deep Insights,Impactful Medicines May 2021 Disclaimers Various statements in this presentation concerning the future expectations, plans and prospects of Scholar Rock, Inc. ("Scholar Rock"), including without limitation, Scholar Rock's expectations regarding its strategy, its p
Read more →SRRKScholar Rock Reports First Quarter 2021 Financial Results and Highlights Business Progress - Apitegromab shows transformative potential in spinal muscular atrophy (SMA) with 74% of patients with non-ambulatory Type 2 and
Scholar Rock Reports First Quarter 2021 Financial Results and Highlights Business Progress - Apitegromab shows transformative potential in spinal muscular atrophy (SMA) with 74% of patients with non-ambulatory Type 2 and 3 SMA in the TOPAZ Phase 2 trial attaining a clinical imp
Read more →SRRKScholar Rock Announces Positive 12-Month Top-Line Results From the TOPAZ Phase 2 Clinical Trial Evaluating Apitegromab in Patients With Type 2 and Type 3 Spinal Muscular Atrophy (SMA) - Data further demonstrate proof-of-
Scholar Rock Announces Positive 12-Month Top-Line Results From the TOPAZ Phase 2 Clinical Trial Evaluating Apitegromab in Patients With Type 2 and Type 3 Spinal Muscular Atrophy (SMA) - Data further demonstrate proof-of-concept for the therapeutic potential of apitegromab in pat
Read more →SRRKScholar Rock Announces the Addition of Joshua Reed to Its Board of Directors CAMBRIDGE, Mass.--(BUSINESS WIRE)
Scholar Rock Announces the Addition of Joshua Reed to Its Board of Directors CAMBRIDGE, Mass.--(BUSINESS WIRE)--March 18, 2021--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors pl
Read more →SRRKScholar Rock Reports Full Year 2020 Financial Results and Highlights Business Progress - TOPAZ Phase 2 interim data demonstrated proof-of-concept for apitegromab in patients with Type 2 and Type 3 spinal muscular atrophy
Scholar Rock Reports Full Year 2020 Financial Results and Highlights Business Progress - TOPAZ Phase 2 interim data demonstrated proof-of-concept for apitegromab in patients with Type 2 and Type 3 spinal muscular atrophy (SMA); 12-month top-line results on-track - SRK-181 DRAGO
Read more →SRRKScholar Rock Reports Third Quarter 2020 Financial Results and Highlights Business Progress - Positive interim analysis data from the TOPAZ Phase 2 trial demonstrated proof-of-concept for apitegromab (SRK-015) in patients
Scholar Rock Reports Third Quarter 2020 Financial Results and Highlights Business Progress - Positive interim analysis data from the TOPAZ Phase 2 trial demonstrated proof-of-concept for apitegromab (SRK-015) in patients with Type 2 and Type 3 Spinal Muscular Atrophy - Progress
Read more →SRRKScholar Rock Announces Proposed Public Offering of Common Stock
Rock Announces Proposed Public Offering of Common Stock Mass.--(BUSINESS WIRE)--Oct. 27, 2020-- Scholar Rock Holding Corporation (Nasdaq: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundam
Read more →SRRKScholar Rock Announces Positive Proof-of-Concept Data from TOPAZ Phase 2 Trial Interim Analysis of SRK-015 in Patients with Type 2 and Type 3 Spinal Muscular Atrophy - Motor function improvements were observed for all th
Scholar Rock Announces Positive Proof-of-Concept Data from TOPAZ Phase 2 Trial Interim Analysis of SRK-015 in Patients with Type 2 and Type 3 Spinal Muscular Atrophy - Motor function improvements were observed for all three SRK-015 treatment cohorts in the primary efficacy endpo
Read more →SRRKScholar Rock Secures $50 million Debt Facility with Silicon Valley Bank and Oxford Finance CAMBRIDGE, Mass.--(BUSINESS WIRE)
Scholar Rock Secures $50 million Debt Facility with Silicon Valley Bank and Oxford Finance CAMBRIDGE, Mass.--(BUSINESS WIRE)--October 19, 2020--Scholar Rock(NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein gr
Read more →SRRKScholar Rock Reports Second Quarter 2020 Financial Results and Highlights Business Progress - On track to report interim efficacy and safety results from TOPAZ Phase 2 clinical trial of SRK-015 in patients with Type 2 an
Scholar Rock Reports Second Quarter 2020 Financial Results and Highlights Business Progress - On track to report interim efficacy and safety results from TOPAZ Phase 2 clinical trial of SRK-015 in patients with Type 2 and Type 3 Spinal Muscular Atrophy (SMA) in 4Q20 - Enrollmen
Read more →SRRKScholar Rock Appoints Tony Kingsley as President and CEO - Nagesh Mahanthappa, Ph.D., MBA, company's founding chief executive, passes the baton after leading company since 2012 - Tony Kingsley, a proven leader with a suc
Scholar Rock Appoints Tony Kingsley as - Nagesh Mahanthappa, Ph.D., MBA, company's founding chief executive, passes the baton after leading company since 2012 - Tony Kingsley, a proven leader with a successful track record of advancing companies, to lead through next phase of c
Read more →SRRKScholar Rock Appoints Tony Kingsley to Its Board of Directors - Proven leader with extensive operational and commercial experience joins expanded Board CAMBRIDGE, Mass.--(BUSINESS WIRE)
Scholar Rock Appoints Tony Kingsley to Its Board of Directors - Proven leader with extensive operational and commercial experience joins expanded Board CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 21, 2020--Scholar Rock (NASDAQ:SRRK), a clinical-stage biopharmaceutical company focuse
Read more →SRRKScholar Rock Reports First Quarter 2020 Financial Results and Highlights Business Progress - Progressing TOPAZ Phase 2 clinical trial of SRK-015 in patients with Spinal Muscular Atrophy; interim efficacy and safety resul
Scholar Rock Reports First Quarter 2020 Financial Results and Highlights Business Progress - Progressing TOPAZ Phase 2 clinical trial of SRK-015 in patients with Spinal Muscular Atrophy; interim efficacy and safety results delayed by approximately one quarter to 4Q20 due to imp
Read more →SRRKScholar Rock Reports Full Year 2019 Financial Results and Highlights Business Progress - Initiated the Phase 1 proof-of-concept clinical trial of SRK-181, a potent and highly selective inhibitor of TGF 1 activation, in p
Scholar Rock Reports Full Year 2019 Financial Results and Highlights Business Progress - Initiated the Phase 1 proof-of-concept clinical trial of SRK-181, a potent and highly selective inhibitor of TGF 1 activation, in patients with locally advanced or metastatic - On track to
Read more →SRRKScholar Rock Presents Data for SRK-015 at the SMA Europe 2nd International Scientific Congress
Scholar Rock presented data on SRK-015 at the SMA Europe Congress, showcasing preclinical and Phase 1 clinical findings. The company highlighted the completion of enrollment in the TOPAZ Phase 2 trial, which aims to evaluate SRK-015's efficacy in treating Type 2 and Type 3 Spinal Muscular Atrophy. Interim results are anticipated mid-year, indicating potential benefits for patients.
Read more →SRRKJanuary 2020 Deep Insights Impactful Medicines
January 2020 Deep Insights Impactful Medicines 3 Our Purpose Relentlessly focused on seeing new possibilities in validated biologies and antibody technologies to allow us to move with speed and urgency to deliver transformative medicines to patients with devastating diseases Dif
Read more →SRRKScholar Rock Provides Corporate Update and Outlines Key R&D Priorities for 2020
Scholar Rock has made significant advancements in its R&D efforts, completing enrollment for the TOPAZ Phase 2 trial of SRK-015 in spinal muscular atrophy and submitting an IND application for SRK-181 aimed at treating solid tumors. The company also reported a successful collaboration with Gilead, earning a $25 million milestone payment. Looking ahead, Scholar Rock plans to initiate a Phase 1 trial for SRK-181 and expects initial clinical data for both SRK-015 and SRK-181 within the year.
Read more →SRRKScholar Rock Achieves First Milestone in Strategic Fibrosis Collaboration with Gilead Sciences
Scholar Rock has successfully demonstrated preclinical proof-of-concept studies, earning a $25 million milestone payment from Gilead Sciences. This collaboration aims to develop selective inhibitors targeting TGFβ activation for fibrotic diseases. Scholar Rock retains rights for certain TGFβ inhibitors and could receive up to $1.425 billion in additional payments based on future milestones.
Read more →SRRKScholar Rock Added to NASDAQ Biotechnology Index
Scholar Rock Holding Corporation (NASDAQ: SRRK) has been added to the NASDAQ Biotechnology Index, effective December 23, 2019. This inclusion highlights the company's focus on developing innovative medicines for serious diseases, including neuromuscular disorders and cancer. Scholar Rock's lead candidates, SRK-015 and SRK-181, aim to address significant medical needs through targeted therapies.
Read more →SRRKScholar Rock Reports Preliminary Pharmacokinetic and Pharmacodynamic Data from TOPAZ Phase 2 Trial of SRK-015 for the Treatment of Patients with Spinal Muscular Atrophy
Scholar Rock announced preliminary pharmacokinetic and pharmacodynamic results from the TOPAZ Phase 2 trial of SRK-015 for spinal muscular atrophy (SMA). The trial demonstrated dose-proportional drug exposure and significant target engagement, with increases in latent myostatin levels. The ongoing trial aims to assess safety and motor function outcomes in SMA patients, with interim results expected in early 2020.
Read more →SRRKNovember 2019 From New Insights to New Medicines
November 2019 From New Insights to New Medicines 3 Novel Approach to S elective M odulation of Growth F actor S ignaling Traditional Target "Mature" Growth Factor Scholar Rock's Target Growth Factor Precursor (Latent Form) but have been limited by: Structural similarities Overla
Read more →SRRKScholar Rock Reports Third Quarter 2019 Financial Results and Highlights Business Progress
Scholar Rock reported its Q3 2019 financial results, highlighting progress in its pipeline, particularly with SRK-181. The company plans to initiate a Phase 1 trial for this candidate in early 2020. Despite a net loss of $16.1 million, Scholar Rock maintains a strong cash position. The firm is focused on achieving key milestones in the upcoming year.
Read more →SRRKScholar Rock to Present at the 2019 Jefferies London Healthcare Conference
Scholar Rock Holding Corporation will present at the 2019 Jefferies London Healthcare Conference on November 20, 2019. The presentation will focus on the company's innovative approach to treating serious diseases through the development of monoclonal antibodies targeting protein growth factors. A live webcast will be available, with an archived replay accessible for 90 days post-event.
Read more →SRRKScholar Rock to Present Preclinical and Phase 1 Clinical Data on SRK-015 at the World Muscle Society Congress
Scholar Rock announced the presentation of preclinical and Phase 1 clinical data for SRK-015 at the World Muscle Society Congress. This selective myostatin inhibitor is being evaluated for treating spinal muscular atrophy (SMA). The company is optimistic about SRK-015's potential as a muscle-directed therapy and looks forward to upcoming trial results.
Read more →SRRKScholar Rock Announces Appointment of George Nomikos, M.D., Ph.D., as Vice President, Head of Medical Research, Muscle Franchise
Scholar Rock has appointed Dr. George Nomikos as Vice President and Head of Medical Research for its Muscle Franchise. Dr. Nomikos brings 35 years of experience in neuroscience and drug development, previously working at Biogen and Sage Therapeutics. He will lead the SRK-015 program for spinal muscular atrophy, which is currently in Phase 2 trials.
Read more →SRRKScholar Rock to Present at Upcoming Healthcare Conferences
Scholar Rock Holding Corporation (NASDAQ: SRRK) has announced its participation in upcoming investor conferences. The company is dedicated to developing innovative therapies targeting serious diseases influenced by protein growth factors. Their proprietary platform aims to create monoclonal antibodies that selectively target these proteins, potentially transforming patient care in various conditions.
Read more →SRRKScholar Rock Announces Upcoming Departure of Chief Financial Officer
CAMBRIDGE, Mass., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (Nasdaq: SRRK), a clinical stage biopharmaceutical company, announced today that its Chief Financial Officer, Rhonda Chicko, will be leaving the Company to pursue other opportunities. She will co
Read more →SRRKScholar Rock Reports Second Quarter 2019 Financial Results and Highlights Business Progress
Enrollment on track in the TOPAZ Phase 2 clinical trial of SRK-015 in patients with Type 2 and Type 3 Spinal Muscular Atrophy for preliminary PK/PD results by year-end Presented positive final results from the Phase 1 clinical trial of SRK-015 in healthy volunteers at the Cure S
Read more →SRRKScholar Rock to Present at the 2019 Wedbush PacGrow Healthcare Conference
CAMBRIDGE, Mass., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management wi
Read more →SRRKScholar Rock Announces Exercise in Full of Underwriters’ Option to Purchase Additional Shares of Common Stock in Public Offering
CAMBRIDGE, Mass., July 02, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (Nasdaq: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the underwrit
Read more →SRRKF r o mN e wI n s i ghtst oN e wM e d i ci ne s June 2019 Disclaimers Various statements in this presentation concerning Scholar Rock s future expectations, plans and prospects, including without limitation, Scholar Rock
A Novel Approach to Targeting Growth Factor Signaling Traditional approaches to targeting growth factors have been limited by: Structural similarities Overlapping sets of related receptors Diverse and overlapping physiological roles Scholar Rock s novel approach: Targeting signal
Read more →SRRKScholar Rock Announces Pricing of Public Offering of Common Stock
CAMBRIDGE, Mass., June 19, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (Nasdaq: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the pricing of an
Read more →SRRKScholar Rock to Present at the 2019 BMO Prescriptions for Success Healthcare Conference
CAMBRIDGE, Mass., June 19, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management wi
Read more →SRRKScholar Rock Announces Positive Final Results from Phase 1 Clinical Trial of SRK-015 in Healthy Volunteers
- SRK-015 was well-tolerated in healthy volunteers across all tested doses, supporting evaluation in the ongoing Phase 2 TOPAZ trial in Spinal Muscular Atrophy (SMA) - Pharmacodynamic results from the completed multiple-ascending dose portion of the trial show robust and durab
Read more →SRRKScholar Rock to Present at the Jefferies 2019 Global Healthcare Conference
CAMBRIDGE, Mass., May 28, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management wil
Read more →SRRKScholar Rock Reports First Quarter 2019 Financial Results and Highlights Business Progress
Commenced patient enrollment and dosing in TOPAZ, the Phase 2 clinical trial for SRK-015 in Type 2 and Type 3 Spinal Muscular Atrophy (SMA) Presented additional preclinical data from the SRK-181 cancer immunotherapy program at the American Association for Cancer Research (AACR)
Read more →SRRKScholar Rock Announces Initiation of Patient Dosing in Phase 2 Trial of SRK-015 in Spinal Muscular Atrophy
Dosing of patients has commenced in TOPAZ, the Phase 2 clinical trial of SRK-015 in Type 2 and Type 3 Spinal Muscular Atrophy (SMA) Preliminary PK/PD data from a subset of patients are anticipated by year-end 2019 Interim safety and efficacy analysis of a subset of patients wit
Read more →SRRKScholar Rock Appoints Akshay Vaishnaw, M.D., Ph.D. to Its Board of Directors
CAMBRIDGE, Mass., April 30, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that Akshay Vaish
Read more →SRRKScholar Rock Announces Appointment of Lisa Amaya Price as Senior Vice President, Human Resources
CAMBRIDGE, Mass., April 11, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the appointment o
Read more →SRRKScholar Rock Reports Full Year 2018 Financial Results and Highlights Business Progress
Initiated and Progressed Phase 1 Clinical Trial of SRK-015 in Healthy Volunteers, Transitioning to a Clinical-Stage Company Presented Compelling Preclinical Data from the SRK-181 Cancer Immunotherapy Program at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting
Read more →SRRKMarch 2019 From New Insights to New Medicines
March 2019 From New Insights to New Medicines 3 2018: Transformative Year for Scholar Rock Established Strong Financial Foundation Transitioned to public company with successful $86M IPO Transitioned to Clinical - Stage Company SRK - 015 Phase 1 trial supports advancement to Pha
Read more →SRRKScholar Rock to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., March 06, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management w
Read more →SRRKScholar Rock Announces Positive Interim Results from Phase 1 Trial of SRK-015 in Healthy Volunteers and Updates on Future Development Plans
Favorable Safety Profile Across All Tested Doses Supports Initiation of a Phase 2 Trial in Patients with Spinal Muscular Atrophy (SMA) Pharmacodynamic Results Demonstrate Robust and Sustained Target Engagement of Latent Myostatin Phase 2 Trial Initiation Expected by the End of
Read more →SRRKScholar Rock to Present at the 37th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management wi
Read more →SRRKScholar Rock Announces Positive Opinion by the European Medicines Agency on Orphan Drug Designation for SRK-015 for the Treatment of Spinal Muscular Atrophy
CAMBRIDGE, Mass., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the European
Read more →SRRKScholar Rock to Present at the BMO 2018 Prescriptions for Success Healthcare Conference
CAMBRIDGE, Mass., Nov. 29, 2018 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management wi
Read more →SRRKScholar Rock Announces Publication of Preclinical Data on the Therapeutic Benefit of Inhibiting Myostatin Activation in Models of Spinal Muscular Atrophy
CAMBRIDGE, Mass., Nov. 27, 2018 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the publication, “
Read more →SRRKScholar Rock Announces the Addition of Edward (Ted) Myles to Its Board of Directors
CAMBRIDGE, Mass., Nov. 19, 2018 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that Edward (Ted)
Read more →SRRKAugust 2018 From New Insights to New Medicines
August 2018 From New Insights to New Medicines 2 Disclaimers Various statements in this presentation concerning Scholar Rock's future expectations, plans and prospects, including without limitation, Scholar Rock's expectations regarding its strategy, its product candidate select
Read more →SRRKScholar Rock Reports Second Quarter 2018 Financial Results and Updates on Business Progress
Completed Initial Public Offering Raising $86.3 Million in Gross Proceeds Initiated Enrollment in Multiple-Ascending Dose Portion of Phase 1 Clinical Trial for SRK-015 On Track to Initiate Phase 2 Proof-of-Concept Study in Later-Onset SMA in 1Q19 Cash and Cash Equivalents of $
Read more →Competitive Position
How SRRK ranks across every disease it competes inCompetitive Position is a premium feature
See how SRRK ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial